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Liver disease is one of the leading causes of death worldwide 1 . Patients with cirrhosis display an increased predisposition to and mortality from infection due to multimodal defects in the innate immune system [2] [3] [4] ; however, the causative mechanism has remained elusive. We present evidence that the cyclooxygenase (COX)-derived eicosanoid prostaglandin E 2 (PGE 2 ) drives cirrhosis-associated immunosuppression. We observed elevated circulating concentrations (more than seven times as high as in healthy volunteers) of PGE 2 in patients with acute decompensation of cirrhosis. Plasma from these and patients with end-stage liver disease (ESLD) suppressed macrophage proinflammatory cytokine secretion and bacterial killing in vitro in a PGE 2 -dependent manner via the prostanoid type E receptor-2 (EP2), effects not seen with plasma from patients with stable cirrhosis (Child-Pugh score grade A). Albumin, which reduces PGE 2 bioavailability, was decreased in the serum of patients with acute decompensation or ESLD (<30 mg/dl) and appears to have a role in modulating PGE 2 -mediated immune dysfunction. In vivo administration of human albumin solution to these patients significantly improved the plasma-induced impairment of macrophage proinflammatory cytokine production in vitro. Two mouse models of liver injury (bile duct ligation and carbon tetrachloride) also exhibited elevated PGE 2 , reduced circulating albumin concentrations and EP2-mediated immunosuppression. Treatment with COX inhibitors or albumin restored immune competence and survival following infection with group B Streptococcus. Taken together, human albumin solution infusions may be used to reduce circulating PGE 2 levels, attenuating immune suppression and reducing the risk of infection in patients with acutely decompensated cirrhosis or ESLD.
The prevalence of liver disease is predicted to rise dramatically as a consequence of the global trends of obesity, higher alcohol consumption and rising hepatitis C virus transmission 1 . Bacterial infection represents a key cause of early death in individuals with cirrhosis, precipitating 50% of hospital admissions, with a further 15-35% developing nosocomial infections as inpatients 5 . Secondary sepsis and requirement for multiorgan support in intensive care is associated with 65-90% mortality 6 . The dysfunction of both neutrophils and monocytes in cirrhosis has long been recognized to underlie this, and the presence of an inhibitory humoral mediator has been speculated upon, yet not definitively identified [7] [8] [9] .
Patients with cirrhosis are markedly heterogeneous, with critical variations in etiology and disease stage. Susceptibility to infection, reflecting immune dysfunction, is highest in patients with acutely decompensated cirrhosis and lowest in stable cirrhosis 10 . Patients with decompensated cirrhosis may present with hepatic encephalopathy, ascites, variceal bleeding, alcoholic hepatitis and hyperbilirubinemia. Acute decompensation is defined by the acute development of one or more of these complications and includes acute-on-chronic liver failure (AoCLF 4 ). Immunomodulatory therapy to both prevent and treat infections in the most vulnerable groups could reduce early mortality and thus reduce the health-economic burden of liver cirrhosis in the twenty-first century.
Inflammation-driven COX-derived lipid mediators exert diverse effects on the innate immune system that may account for increased infective susceptibility in patients with cirrhosis [11] [12] [13] [14] . In particular, PGE 2 has widespread immunomodulatory roles dependent on its site of action and formation and has been shown to be a key mediator of myeloid-derived cell dysfunction inhibiting NADPH oxidase-mediated bacterial killing 15, 16 via upregulation of cAMP and inhibition of FcγR-mediated phagocytosis 17, 18 .
Using electrospray ionization liquid chromatography-tandem mass spectrometry (ESI/LC-MS/MS) to analyze plasma obtained from patients with acutely decompensated cirrhosis on days 1-2 of hospital admission (AD plasma) as compared to plasma from healthy volunteers (HV plasma), we detected significantly elevated PGE 2 , PGF 2 α, 5-hydroxyeicosatetraenoic acid (5-HETE) and 15-HETE, but no changes in thromboxane B 2 , 9-hydroxyoctadecadienoic acid (9-HODE), 12-HETE and 13-HODE, in the AD plasma ( Fig. 1a and Supplementary Fig. 1a-g ). Of these, only PGE 2 dampened the release of tumor necrosis factor-α (TNF-α) from lipopolysaccharide (LPS)-stimulated human monocyte-derived macrophages (MDMs) at the concentrations observed in patient plasma (0.1 ng/ml) (Fig. 1b) . LPS-stimulated TNF-α release from MDMs was significantly decreased by incubation with culture medium supplemented with 25% (vol/vol) AD plasma (Supplementary Table 1 for clinical characteristics) relative to HV plasma, an effect reversed by the addition of AH6809, an antagonist to prostanoid type E receptors 1-3 and prostanoid type D receptor-1 (Fig. 1c) . Macrophages were also incubated with Escherichia coli (clinical isolate). Compared to macrophages treated with HV plasma, those incubated with AD plasma exhibited reduced bacterial killing, an effect again reversed by pretreatment with AH6809 (50 µM) (Fig. 1d) . AH6809 had no direct bactericidal effect when cell viability was unaffected by plasma from either these patients or healthy volunteers.
AD plasma showed persistent PGE 2 -mediated immunosuppression up to day 6 after admission, leading to reduced MDM TNF-α and elevated interleukin-10 (IL-10) production (Fig. 1e,f) . Notably, although ~60% of day 1 AD plasma samples reduced MDM TNF-α release (Fig. 1c) , all patient plasma sampled from days 2-6 did so in a PGE 2 -dependent manner (Fig. 1e,f) . PGE 2 also mediated immunosuppression in patients with ESLD; plasma from patients with ESLD taken 24 weeks apart significantly impaired macrophage TNF-α synthesis, an effect blocked by AH6809 (Fig. 2a) . In contrast, samples from outpatients with Child-Pugh score grade A cirrhosis or noncirrhotic liver disease had no effect on macrophage function (Fig. 2b) .
Compared to HV plasma, PGE 2 levels were twice as high in the plasma of patients with Child-Pugh score grade A cirrhosis but were seven times higher in AD plasma ( Fig. 1a and Supplementary Table 2) .
Real-time PCR (rtPCR) revealed increased expression of COX-2 (P < 0.00001) but not COX-1 in peripheral blood mononuclear cells (PBMCs) of patients with acute decompensation compared to healthy volunteers (n = 5 per group, Fig. 2c ). Immunohistochemical analysis of all organs from a mouse model of cirrhosis (carbon tetrachloride (CCL 4 ), which induces elevated PGE 2 in the plasma (Fig. 2d) , demonstrated upregulation of COX-2 in Kupffer cells and alveolar macrophages, but not in other cell types, compared to those from sham mice (treated with olive oil) (Fig. 2e,f) , suggesting that PBMCs, Kupffer cells and alveolar macrophages are the likely sources of PGE 2 . We found that inhibiting PGE 2 increased bacterial killing and restored survival in two animal models of liver injury. Although an imperfect experimental model, mice that have undergone bile duct ligation (BDL) do exhibit certain similarities to patients with acutely decompensated cirrhosis (for example, high bilirubin and low albumin (Supplementary Table 3) ) and were found to have at least fivefold higher plasma concentrations of PGE 2 ( Fig. 2d) but not other eicosanoids compared to naive and sham mice ( Supplementary Fig. 2a-p) . As in humans, BDL plasma suppressed macrophage TNF-α and increased IL-10 production ( Fig. 3a and Supplementary Fig. 3a,b) without affecting macrophage viability. This was prevented if the mice were pretreated with the nonselective COX inhibitor indomethacin but not baicalein (12-lipoxygenase inhibitor), SKF525A (p450 inhibitor) or l-NAME (nitric oxide synthase inhibitor) or if BDL plasma was heat treated (protein denatured). Again, as in humans, immunosuppression was mediated in a PGE 2 and IL-10 (f) release from human MDMs stimulated with LPS in the presence of plasma from patients with AD (day 2-6 (D2-D6) of admission) and healthy volunteers with or without AH6809 (AH, 50 µM) (for AD plasma, n = 13 patients on day 2, n = 6 on day 3, n = 4 on day 4 and n = 3 on days 5 and 6). Data are represented as mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001, analysis of variance (ANOVA). Fig. 3c-i) . Experiments using CCL 4 -treated mice showed similar PGE 2 -mediated immunosuppressive effects of plasma from mice with liver injury (Fig. 3b ) combined with significantly elevated plasma PGE 2 (Fig. 2d) . PGD 2 was also elevated in CCL 4 mouse plasma (Supplementary Fig. 4a ) but not other eicosanoids ( Supplementary Fig. 4b-p) . We injected BDL mice with live Streptococcus agalactiae (group B Streptococcus) (GBS, NCTC10/84, serotype V). Consistent with immunosuppression, bacterial counts were significantly elevated in BDL blood compared to mice that underwent a sham procedure (Fig. 3c,d ). Treating BDL mice with indomethacin intraperitoneally (i.p.) or intravenously (i.v.) (inhibiting PGE 2 concentration by >80%) 1 h before GBS administration restored bacterial killing to sham levels ( Fig. 3c,d ). Indomethacin also improved survival following GBS challenge in BDL mice to that of sham mice (Fig. 3e) . In the lung, PGE 2 protects against fibrosis 19 and therefore reducing levels may worsen liver fibrosis. However, histological analysis with H&E and Masson's trichrome staining showed no difference in liver pathology between mice treated with celecoxib (selective COX-2 inhibitor) for 5 d after final CCL 4 injection and non-celecoxib-treated CCL 4 mice (Fig. 3f,g ).
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Correlating the concentration of TNF-α in the supernatant from macrophages incubated in the presence of AD plasma with corresponding plasma PGE 2 levels notably resulted in a modest r 2 of only 0.41 (P = 0.085). Albumin, hepatically synthesized and frequently reduced in liver disease, is known to bind types A and E prostaglandins at the ligand-binding site I in subdomain 2A (ref. 20) . We postulated that immunosuppression might be a consequence of the bioavailability of PGE 2 determined by blood albumin concentration. Expressing AD plasma PGE 2 levels according to the corresponding albumin levels and then correlating these values with the concentration of TNF-α in the macrophage supernatant resulted in an r 2 value of 0.72 (P = 0.0076) (Fig. 4a) . Adding albumin to AD plasma in order to restore the concentration of albumin to 40 mg/dl (equivalent to that of healthy volunteers) reversed AD plasma-induced suppression of TNF-α by MDMs (Fig. 4b) . Furthermore, supplementing culture medium with 40 mg/dl of albumin impaired PGE 2 -mediated inhibition of TNF-α release (Fig. 4c) .
To further define this relationship, we grouped AD plasma samples into those derived from the most immunosuppressed (MIS) patients (samples that dampened TNF-α below the lowest TNF-α induced by healthy plasma) (Fig. 4a) and those from the least immunosuppressed (LIS) patients (the remainder) (Fig. 4d) . Addition of albumin or AH6809 reversed immunosuppression in AD plasma samples derived from MIS patients, but not in samples from LIS patients (Fig. 4d and Supplementary Fig. 5a-c) . We also observed this differential effect of AH6809 on samples from LIS and MIS patients with ESLD (Supplementary Fig. 5d ). Analysis of data from patients with acutely decompensated cirrhosis (Supplementary Table 1) demonstrated that albumin was the only feature that discriminated between MIS and LIS plasma samples (P = 0.0012). Notably, the conventional markers of advanced liver disease-model for end-stage liver disease (MELD) score, bilirubin or international normalized ratio (INR)-did not differentiate between MIS and LIS in patients with acute decompensation (Supplementary Table 1) . Receiver operating characteristic (ROC) analysis of this cohort of 35 patients revealed that a cut-off albumin level of <30 mg/dl predicted immunosuppression with a sensitivity of 70% (confidence interval (CI) = 47-87) and a specificity of 67% (CI = 35-90).
To examine the therapeutic potential of albumin, we treated BDL mice with 20% human albumin solution (HAS) or 0.9% saline (0.5 ml, i.p.) 2 h before GBS challenge. In HAS-treated mice, the mean plasma albumin concentrations rose from 24 mg/dl to 32 mg/dl. HAS npg treatment resulted in significantly lower levels of blood bacteria 3 h after GBS challenge compared to that seen in mice treated with saline instead of HAS (Fig. 4e) . The plasma PGE 2 concentration was slightly reduced in HAS-treated mice (Fig. 4f) , but, as PGE 2 measured in plasma reflects both free and albumin-bound PGE 2 , the effect of albumin on the immune system may be unrelated to total plasma PGE 2 concentration. As albumin has no direct bactericidal effect (data not shown), we suggest that it improves immune competence in BDL mice by reducing PGE 2 bioavailability. 20% HAS given to patients admitted to hospital with acutely decompensated cirrhosis (median 200 ml) with serum albumin <30 mg/dl raised albumin levels from 23.7 ± 1.7 to 30.1 ± 3.1 mg/ml and reduced in vitro evidence of immunosuppression ( Fig. 4g , P < 0.05, n = 6). Matched samples from patients not given albumin demonstrated persistent immunosuppression. In patients admitted with acute hepatic encephalopathy, we observed that plasma-induced immunosuppression persisted for up to 60 d following discharge (P < 0.001, Fig. 4h ) and that administration of 20% HAS to all patients on day 1 (1.5 g per kg body weight (g/kg)) and again on day 3 (1 g/kg) following admission had no effect on long-term immunosuppression (with blood samples taken on day of admission, one follow-up sample taken between days 8 and 10 after admission and a second follow-up sample taken between days 30 and 60 after admission). Saline had no effect (Supplementary Fig. 5e ).
Taken together, these findings implicate increased bioavailability of PGE 2 as a primary contributor to innate immune dysfunction and thus vulnerability to infection in cirrhotic patients presenting with acute decompensation and in ESLD. We accept that it is highly likely that other mediators may also be responsible for cirrhosis-induced immunosuppression, such as circulating endotoxin secondary to bacterial translocation 21 . However, we suggest that elevated PGE 2 is likely to represent a driver of immunosuppression and offers a potential target for immunomodulatory therapy. Our studies reveal the likely source of PGE 2 to be PBMCs, liver Kupffer cells and alveolar macrophages. Increased PGE 2 production may be triggered by a combination of liver injury-related inflammatory cell infiltrates and bacterial translocation from the gut resulting in elevated COX activity in these cell types 22 . The immunosuppressive effect of PGE 2 was associated with reduced serum albumin concentration in patients with acutely decompensated cirrhosis. Albumin is known to bind and accelerate metabolism of E-series prostaglandins, and its reduction may be expected to result in elevated PGE 2 bioavailability 20 . This relationship may explain why plasma from patients with stable cirrhosis had no immunosuppressive effects despite elevated PGE 2 (twice control values); this population is protected by normal albumin concentrations. Despite the apparent antifibrotic properties of PGE 2 (ref. 23 ), 5 d of COX-2 inhibition did not worsen liver fibrosis.
We observed PGE 2 -mediated immunosuppression in >75 patients with either acutely decompensated cirrhosis or ESLD recruited from five sites in two countries and in almost all patients with acute decompensation from day 2 of their admission until at least 60 d following discharge. In this population, a serum albumin concentration <30 mg/dl may be predictive of immunosuppression (reflecting an inverse correlation with PGE 2 bioavailability). Notably, we have demonstrated that 20% HAS infusions given in vivo to achieve a concentration above 30 mg/dl improves (albeit temporarily) immune Figure 3 Inhibiting PGE 2 restores bacterial killing and survival following bacterial infection in mouse models of liver injury. (a) TNF-α release from peritoneal macrophages from naive mice stimulated with LPS in the presence of plasma from naive mice or BDL mice with or without administration of indomethacin, SKF525A, baicalein or l-NAME before blood sampling (n = 11 cells alone and n = 13 cells + LPS; n = 9 naive mice plasma; n = 8 BDL mice plasma; n = 4 plasma from indomethacin-treated BDLs; n = 6 plasma from SKF525A-treated BDLs; n = 6 plasma from l-NAME-treated BDLs; n = 4 plasma from baicalein-treated BDLs). npg l e t t e r S competency, reversing AD plasma-induced impairment of cytokine production ex vivo. In addition, in in vivo mouse models antagonizing the effects of PGE 2 using either 20% HAS or indomethacin restored bacterial killing and survival to sham levels. Although effective experimentally, nonsteroidal anti-inflammatory drugs are contraindicated in patients with advanced cirrhosis owing to increased incidence of renal impairment and gastrointestinal bleeding 24 . Albumin, already safely used to treat cirrhosis-associated complications such as spontaneous bacterial peritonitis 25 , appears to selectively antagonize PGE 2 's effects on the immune system without compromising its protective role in other tissues. Albumin was recently suggested to exert multimodal beneficial effects in individuals with cirrhosis 26, 27 , and we provide mechanistic insight into one of these: its immune restorative properties. Stratified, targeted HAS therapy to achieve and maintain serum concentrations at near normal concentrations may thus represent an elegant, cheap and rapidly implementable management paradigm to ameliorate PGE 2 -induced innate immune impairment by both preventing and treating infection in patients presenting with acute decompensation. HAS may also represent a therapeutic strategy in patients with ESLD 28 . These management paradigms would clearly require validation by largescale clinical trials.
METhODS
Methods and any associated references are available in the online version of the paper. HAS on days 1 (1.5 g/kg) and 3 (1 g/kg) after admission with samples obtained on day 1 of admission and at follow-up, with one sample taken between days 8 and 10 and a second between days 30 and 60 after admission (n = 10 at day 1 and n = 8 at days 8-10 and 30-60, as two lost to follow-up; n = 13 HV). Data are represented as mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001, ANOVA. 
